More links - have a feeling they're going to get there with this kind of momentum. It provides an interesting possible alternative funding model to the patent

More links - have a feeling they're going to get there with this kind of momentum. It provides an interesting possible alternative funding model to the patent driven one. Would be better if there was some breakdown of the costs involved though, and a few more endorsements from scientists of the approach. https://twitter.com/iCancerVirus https://twitter.com/iCancerVirus http://www.guardian.co.uk/science/occams-corner/2012/oct/08/icancer-cancer-public-funding http://www.guardian.co.uk/science/occams-corner/2012/oct/08/... http://www.indiegogo.com/icancervirus http://www.indiegogo.com/icancervirus <- the campaign page http://www.netpatientfoundation.org/2012/10/icancer-campaign-launches-today-on-the-anniversary-of-steve-jobs-death/ http://www.netpatientfoundation.org/2012/10/icancer-campaign... <- with a link to a professor's view on this approach and others under development http://www.telegraph.co.uk/health/9581988/The-cancer-killer-they-wont-pay-for.html http://www.telegraph.co.uk/health/9581988/The-cancer-killer-... http://www.telegraph.co.uk/health/9544400/Would-I-takean-untested-cancer-treatment-myself-Hellyes.html http://www.telegraph.co.uk/health/9544400/Would-I-takean-unt... http://mashable.com/2012/10/05/steve-jobs-philanthropy/ http://mashable.com/2012/10/05/steve-jobs-philanthropy/ Papers (from the Indiegogo page): PAPER I A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy. <http://www.ncbi.nlm.nih.gov/pubmed/17438105&#62 http://www.ncbi.nlm.nih.gov/pubmed/17438105> Leja J, Dzojic H, Gustafson E, Oberg K, Giandomenico V, Essand M. Clin Cancer Res. 2007 Apr 15;13(8):2455-62. PAPER II Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability. <http://www.ncbi.nlm.nih.gov/pubmed/20111709&#62 http://www.ncbi.nlm.nih.gov/pubmed/20111709> Leja J, Nilsson B, Yu D, Gustafson E, Akerström G, Oberg K, Giandomenico V, Essand M. PAPER III Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors. <http://www.ncbi.nlm.nih.gov/pubmed/21957304&#62 http://www.ncbi.nlm.nih.gov/pubmed/21957304> Yu D, Jin C, Leja J, Majdalani N, Nilsson B, Eriksson F, Essand M. J Virol. 2011 Dec;85(24):13114-23. Epub 2011 Sep 28. PAPER IV Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells. <http://www.ncbi.nlm.nih.gov/pubmed/21490682&#62 http://www.ncbi.nlm.nih.gov/pubmed/21490682> Leja J, Yu D, Nilsson B, Gedda L, Zieba A, Hakkarainen T, Åkerström G, Öberg K, Giandomenico V, Essand M. Gene Ther. 2011 Nov;18(11):1052-62. doi: 10.1038/gt.2011.54. Epub 2011 Apr 14.